Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on July 8, 2020. The filing discloses the entry into an acquisition agreement to purchase Healthfinch, Inc., a Delaware corporation. Health Catalyst is an emerging growth company listed on the Nasdaq Global Select Market under the symbol HCAT.
Key Financial Metrics and Transaction Details
The filing details a specific corporate transaction rather than periodic financial results. Key metrics related to the acquisition include:
- Aggregate Purchase Price: Approximately $40 million.
- Equity Consideration: Issuance of 796,380 shares of Health Catalyst Common Stock to Healthfinch stockholders.
- Earnout Provision: Potential issuance of additional shares based on performance targets met during an earnout period ending on the later of July 31, 2021, or the one-year anniversary of the closing.
- Valuation for Earnout: Common Stock valued at $28.88 per share (average trading price for the 35 consecutive trading days ended July 1, 2020).
- Expected Financial Impact: Management does not expect Healthfinch to have a material impact on Health Catalyst's GAAP revenue or adjusted EBITDA in 2020.
The filing text does not provide clear values for the company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Outlook
The primary material change is the pending acquisition of Healthfinch. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2020. The issuance of shares is being made in reliance on the private offering exemption of Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D.
Risks and Contingencies
Management highlights several risks and contingencies associated with the transaction:
- Closing Risks: The transaction is subject to customary closing conditions and may not be completed.
- Integration Risks: Uncertainties related to the integration of the two companies.
- Macro-Economic Conditions: Adverse and unpredictable macro-economic conditions could affect the transaction or future results.
- Forward-Looking Statements: Actual results may differ materially from expectations due to these risks. Health Catalyst disclaims any obligation to update these statements.
Key Facts for Investor Verification
- Verify the closing of the Healthfinch acquisition in Q3 2020 and the final number of shares issued.
- Monitor the earnout performance targets to determine if additional shares will be issued beyond the initial 796,380.
- Confirm the actual financial impact of the acquisition on 2020 GAAP revenue and adjusted EBITDA, despite management's current expectation of no material impact.
- Review subsequent filings for updates on integration progress and any changes to the transaction terms.